Wire story
Amplia gets nod for new cancer drug trial ahead of US push
Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.
Carried by 2 outlets in 1 country
The Sydney Morning Herald
(AU)
·
The Age
(AU)
·